Grace DeSantis, PhD; Jackie Hogan-Schlientz, RN, BSN; Gary Liska, BS; Shari Kipp, BS; Ramarion Sallee; Mark Wurster, MD; Kenneth Kupfer, PhD; and Jack Ansell, MD
Real-world retrospective analysis of over 29,000 patients performing INR home monitoring for warfarin therapy shows excellent time in therapeutic range.
Dana P. Goldman, PhD; Riad Dirani, PhD; John Fastenau, MPH, RPh; and Ryan M. Conrad, PhD
This study measures the impact of Medicaid formulary restrictions on the rate at which patients who failed on a drug therapy for schizophrenia return to the same therapy.
Michael R. McKellar, BA; Michael E. Chernew, PhD; and A. Mark Fendrick, MD
This commentary discusses why antibiotics and the treatment of infectious diseases present a special case for pharmaceutical development, pricing, and appropriate utilization.
Judy H. Ng, PhD; Arlene S. Bierman, MD, MS; Marc N. Elliott, PhD; Rachel L. Wilson, MPH; Chengfei Xia, MS; and Sarah Hudson Scholle, DrPH
This study examines disparities in important patient-reported functional outcomes not routinely assessed among diverse racial/ethnic groups in Medicare managed care.
Christopher S. Hollenbeak, PhD; Mark G. Weiner, MD; and Barbara J. Turner, MD, MSED
A cost-effectiveness analysis of a peer and practice staff support intervention to reduce coronary heart disease risk and blood pressure in African Americans.
*Caterina F. Hill, MSc, MA (Cantab); *Brian W. Powers, AB; Sachin H. Jain, MD, MBA; Jennifer Bennet, BS; Anthony Vavasis, MD; and Nancy E. Oriol, MD (*Joint first authors)
This article reviews the mobile clinic sector's impact on access, quality, and costs, and explores postreform opportunities for leveraging them nationally.
Susannah Higgins, MS; Ravi Chawla, MBA; Christine Colombo, MBA; Richard Snyder, MD; and Somesh Nigam, PhD
A longitudinal case-control design was used to evaluate the effects of the patient-centered medical home model on medical costs and utilization among high-risk patients.
Lauren Brophy, PharmD, FAHM; Amanda Williams, PharmD; Eric J. Berman, DO, MS; David Keleti, PhD; Karen E. Michael, RN, MSN, MBA; Margaret Shepherd, RPh, FAHM; Scott A. Fox, MS, MEd; Christine Jacobs, MA; Susan Tan-Torres, MD, MPH; Andrea D. Gelzer, MD; and Mesfin Tegenu, MS, RPh
Drug therapy management implementation in 2 health plans resulted in significant cost savings and modest to significant reductions in emergency department visits and inpatient admissions among patients with diabetes.
Rebecca J. Williams, DrPh; Andrew L. Masica, MD; Mary Ann McBurnie, PhD; Leif I. Solberg, MD; Steffani R. Bailey, PhD; Brian Hazlehurst, PhD; Stephen E. Kurtz, PhD; Andrew E. Williams, PhD; Jon E. Puro, MHA-PA; and Victor J. Stevens, PhD
Evaluation of the 5 As of smoking cessation using patient electronic medical records across 6 distinct healthcare systems, stratified by comorbidity, gender, age, race ethnicity.
Walid F. Gellad, MD, MPH; Phillip Choi, BS; Margaret Mizah, PharmD; Chester B. Good, MD, MPH; and Aaron S. Kesselheim, MD, JD, MPH
From 2001 to 2011, the US Food and Drug Administration approved 9 single-enantiomer drugs with racemic precursors. None showed pre-approval evidence of improved efficacy over the racemic precursor.